Leading Companies in India Multiple Myeloma Market | Competitive Landscape 2026

India Multiple Myeloma Market Overview

According to 6Wresearch, the India multiple myeloma market is witnessing steady growth due to increasing cancer prevalence, improving diagnostic capabilities, and rising access to advanced oncology therapies. Growth is further supported by expanding healthcare infrastructure, government cancer awareness programs, and the availability of targeted therapies such as immunomodulators, proteasome inhibitors, and monoclonal antibodies. The market is also benefiting from increasing clinical research activities and patient access to affordable generic oncology medicines.

Competitive Landscape

The competitive landscape in India multiple myeloma market includes strong domestic pharmaceutical companies and global oncology leaders. Companies compete through R&D investments, hospital partnerships, oncology drug pipelines, and expansion of specialty cancer care distribution networks.

Leading Players Operating in the India Multiple Myeloma Market:

1. Dr. Reddy’s Laboratories

A fast-growing leader in the generic oncology segment that provides high-quality affordable versions of essential myeloma drugs like Lenalidomide, integrating manufacturing excellence with patient assistance programs.

2. Natco Pharma Limited

Caters to the cost-sensitive patient base with a robust portfolio of generic hematology drugs, including Pomalidomide and Bortezomib, emphasizing price transparency and ease of access for local oncology centers.

3. Cipla Limited

Leverages decades of global experience to provide technology-enabled oncology delivery and affordable system processing for the Indian hematology sector through its extensive generic Revlimid portfolio.

4. Intas Pharmaceuticals

A pioneer in the biosimilar space that leverages large-scale production to provide high-precision biologics and specialty oncology injectables for diverse hematological conditions.

5. Sun Pharmaceutical Industries

A global leader in specialty generics that leverages a massive R&D infrastructure to provide diverse therapeutic options for relapsed and refractory myeloma patients across the subcontinent.

6. Zydus Lifesciences

Specializes in specialty injectables and complex generic formulations, delivering reliable care for multiple myeloma through vertically integrated supply chains and its recent expansion into US oncology.

7. Biocon Limited

Provides high-volume manufacturing of biosimilars and biologics, supporting some of the largest oncology care frameworks through affordable monoclonal antibody development and novel cell therapies.

8. Venus Remedies Limited

Recently advanced into higher-value specialty injectables like Plerixafor, a stem cell mobilization therapy critical for autologous transplantation in multiple myeloma patients.

9. Bristol Myers Squibb (BMS)

A global pioneer in hematology, BMS provides market-leading immunomodulators like Revlimid and Pomalyst, handling complex regulatory pathways for advanced therapies in India.

10. Amgen Inc.

A major force in the global oncology space, Amgen focuses on proteasome inhibitors like Kyprolis (Carfilzomib) and innovative bone-strengthening agents for myeloma patients.

11. Takeda Pharmaceutical Company

A historic innovator in oncology, Takeda is renowned for Velcade (Bortezomib) and Ninlaro, which were among the first to revolutionize proteasome inhibition therapy.

12. Johnson & Johnson

Combines global research with advanced biologics, offering Darzalex (Daratumumab), which has set new standards in monoclonal antibody treatment for relapsed cases.